Gérard Marguerie
Directeur/Bestuurslid bij CliniGenetics SA
Profiel
Professor Gérard Marguerie became a Director of Research at the CNRS where he focused on coagulation factors, haemostasis and fibrinolysis.
He also spent three years at the Scripps Clinic in San Diego.
On returning to France, Prof.
Marguerie was appointed as a Director of an INSERM unit in Hematology and then took a CEA (Atomic Energy Agency) appointment as Director of the Department of Structural and Molecular Biology at the Nuclear Center of Research in Grenoble.
He was also appointed as the co-director of the national program on structural biology.
Prof.
Marguerie was a substitute Director of the Life Sciences Division of the Atomic Energy Agency and head of a Functional Genomic Research Unit, he was also appointed as Professor at Evry University (Paris) in cellular biology.
He received several prestigious awards such as the ISTH special young investigator award and the CEA award.
Prof.
Marguerie has worked as a consultant for several pharmaceutical companies.
Actieve functies van Gérard Marguerie
Bedrijven | Functie | Begin |
---|---|---|
CliniGenetics SA
CliniGenetics SA Pharmaceuticals: MajorHealth Technology CliniGenetics SA discovers and develops novel therapeutics for the treatment of cardiovascular, cerebrovascular, and lower limb ischemic diseases. The firm identifies and develops new pathways and products for the treatment of vascular diseases. CliniGenetics was founded in 2000 and is headquartered in Nimes, France. | Directeur/Bestuurslid | 17-12-2009 |
Opleiding van Gérard Marguerie
University of Grenoble | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
CliniGenetics SA
CliniGenetics SA Pharmaceuticals: MajorHealth Technology CliniGenetics SA discovers and develops novel therapeutics for the treatment of cardiovascular, cerebrovascular, and lower limb ischemic diseases. The firm identifies and develops new pathways and products for the treatment of vascular diseases. CliniGenetics was founded in 2000 and is headquartered in Nimes, France. | Health Technology |